OSR Holdings, Inc. 8K

An independent advisor delivered a fairness opinion concluding that the related‑party global license of VXM01 by OSR Holdings/Vaximm to BCM Europe AG on the outlined milestone, royalty and equity terms is financially fair to OSR and its unaffiliated shareholders, subject to conditions on the final agreement.

The filing provides the full written fairness opinion of Avance, Basel GmbH to the board of OSR Holdings, Inc. and its wholly owned subsidiary Vaximm AG regarding a related‑party global license transaction for the cancer immunotherapy asset VXM01, under which Vaximm grants BCM Europe AG (the company’s largest shareholder, acting via an investment fund) an exclusive worldwide license in exchange for up to $815 million in clinical, regulatory and commercial milestones, a development financing facility, a royalty pass-through structure with a negative milestone delta recovery and 15% preferred return, and an equity participation right allowing OSR Holdings to sell up to $15 million of stock at a large premium, with Avance concluding that, subject to specified assumptions and conditions on the final definitive agreement, these financial terms are fair from a financial point of view to OSR Holdings, Vaximm, and OSR’s unaffiliated shareholders.

Filing Facts

CIK

1840425

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-052922

Alert Tier

7